MedTrace Logo

Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)

NCT00234858 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2008-07-15

No results posted yet for this study

Summary

The primary objective of this study is to determine whether impaired glucose tolerance is improved to a greater degree by Tarka than Hyzaar in subjects with metabolic syndrome

Conditions

Interventions

DRUG

trandolapril/verapamil

2/180 mg QD with titration if needed at Week 4 to 4/240 mg QD

DRUG

(Hyzaar) losartan/hydrochlorothiazide

50/12.5 mg QD with titration if needed at Week 4 to 100/25 mg QD

Sponsors & Collaborators

Principal Investigators

  • Global Medical Information · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2006-04-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00234858 on ClinicalTrials.gov